Author Topic: (JAMA) Association of sustained immunotherapy w/disability outcomes in active SPMS  (Read 40 times)

0 Members and 2 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
These researchers are saying that even persons with SPMS might benefit from the disease-modifying drugs.  The study (link below) includes this statement:


Quote
Although this intraindividual variability in disease course makes any individual prognosis difficult, it also offers the possibility that MS with sufficient episodic inflammatory activity remains modifiable with immunotherapy at any stage of disease.


From JAMA Neurology (July 27, 2020), "Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis":



https://bit.ly/2X1lHnI
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
108 Views
Last post March 13, 2019, 02:56:48 pm
by agate
4 Replies
193 Views
Last post November 21, 2019, 07:14:23 am
by agate
0 Replies
39 Views
Last post November 11, 2020, 09:26:40 pm
by agate
0 Replies
23 Views
Last post March 21, 2022, 09:21:08 pm
by agate
0 Replies
19 Views
Last post April 09, 2022, 07:09:40 am
by agate